Product Description
for the Treatment of Hypogonadal Men (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02082197)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Hypogonadism
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| M13-886 | P3 |
Withdrawn |
Hypogonadism |
2015-06-01 |